Merkel Cell Carcinoma: Pembrolizumab as First-Line Treatment

The second most common cause of skin cancer death, Merkel cell carcinoma (MCC) is a rare and lethal cancer that usually metastasizes quickly. Researchers have discovered that the immunotherapy drug pembrolizumab (Keytruda®), which has already been FDA approved as a second-line treatment for MCC, elicits a better response rate and increased progression-free survival compared with chemotherapy as a first-line treatment for this condition. In this multicenter phase II trial (Cancer Immunotherapy Tr...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright ┬ę 2021 Oncology Data Advisor. All rights reserved.